A Phase II, multi-center, randomized, double-blind study of T-4288 in patients with community-acquired pneumonia

Trial Profile

A Phase II, multi-center, randomized, double-blind study of T-4288 in patients with community-acquired pneumonia

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Jan 2017

At a glance

  • Drugs Solithromycin (Primary) ; Levofloxacin
  • Indications Bacterial infections; Community-acquired pneumonia
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Toyama Chemical
  • Most Recent Events

    • 25 May 2016 Status changed from recruiting to completed, according to a Cempra Pharmaceuticals media release.
    • 25 May 2016 Results published in a Cempra Pharmaceuticals media release.
    • 17 Sep 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top